Relay Therapeutics, Inc.
RLAY · NASDAQ
Financial statements
Annual and quarterly income, balance-sheet, cash-flow and key-statistics data.
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2022 FY | 1.38M | -241.62M | -299.28M | -290.51M | -2.59 |
| 2023 FY | 25.55M | -300.84M | -373.00M | -341.97M | -2.79 |
| 2024 FY | 10.01M | -305.43M | -372.47M | -337.71M | -2.36 |
| 2025 FY | 15.36M | 11.80M | -302.74M | -276.48M | -1.61 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2022 FY | 1.10B | 149.55M | 151.79M | 57.74M | 950.22M |
| 2023 FY | 843.98M | 91.98M | 143.74M | 53.47M | 752.00M |
| 2024 FY | 871.30M | 93.50M | 124.29M | 48.50M | 777.79M |
| 2025 FY | 621.33M | 54.27M | 84.02M | 32.46M | 567.06M |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2022 FY | -229.49M | -9.06M | -238.55M | — | -128.33M |
| 2023 FY | -300.32M | -4.13M | -304.44M | — | -7.93M |
| 2024 FY | -249.11M | -2.02M | -251.13M | — | -20.04M |
| 2025 FY | -235.46M | -410.00K | -235.87M | — | -41.05M |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2022 FY | 1.68B | 1.58B | — | — | — |
| 2023 FY | 1.35B | 1.26B | — | — | — |
| 2024 FY | 588.62M | 512.83M | — | — | — |
| 2025 FY | 1.45B | 1.40B | — | — | — |
| 2026-12-31 | — | — | — | — | — |
| 2027-12-31 | — | — | — | — | — |
| 2028-12-31 | — | — | — | — | — |
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2025 Q2 | 677.00K | -60.80M | -76.85M | -70.38M | -0.41 |
| 2025 Q3 | — | -67.89M | -80.39M | -74.15M | -0.43 |
| 2025 Q4 | 7.00M | 6.40M | -60.63M | -54.89M | -0.32 |
| 2026 Q1 | 3.00M | 2.50M | -78.59M | -73.29M | -0.41 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2025 Q2 | 728.84M | 63.18M | 113.94M | 34.18M | 665.66M |
| 2025 Q3 | 670.00M | 62.29M | 91.56M | 33.33M | 607.71M |
| 2025 Q4 | 621.33M | 54.27M | 84.02M | 32.46M | 567.06M |
| 2026 Q1 | 699.61M | 57.43M | 204.59M | 31.57M | 642.18M |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2025 Q2 | -55.26M | -26.00K | -55.29M | — | 20.54M |
| 2025 Q3 | -62.12M | 1.00K | -62.12M | — | -22.38M |
| 2025 Q4 | -44.87M | -1.00K | -44.87M | — | -8.47M |
| 2026 Q1 | -51.11M | — | -51.11M | — | 120.57M |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2025 Q2 | 592.58M | 512.82M | — | — | — |
| 2025 Q3 | 899.87M | 841.64M | — | — | — |
| 2025 Q4 | 1.45B | 1.40B | — | — | — |
| 2026 Q1 | 1.79B | 1.62B | — | — | — |
| 2026-06-30 | — | — | — | — | — |
| 2026-09-30 | — | — | — | — | — |
| 2026-12-31 | — | — | — | — | — |